Bill Baruch's Latest Trades: Eli Lilly, McDonald's, and Palantir

Eli Lilly Investment

• 💡 Eli Lilly was added as a new position due to positive news on its GLP drug testing better than expected.
• 📈 The stock's recent move back above the 200-day moving average signals renewed strength.
• 🎯 The focus is on adding exposure to drug manufacturers within the healthcare sector.

McDonald's Rationale

• 🍟 McDonald's is viewed as a defensive name with mid-20s multiples, showing relative strength against peers.
• 🛡️ The franchise model is expected to maintain firm margins, and the company is considered somewhat recession-proof.
• 💰 Its lower price point makes it a beneficiary of consumers trading down during economic slowdowns.
• 📈 There's a desire to see the stock break out above $320.

Palantir's Strategic Position

• 🚀 Palantir was initiated as a new position and has shown strong relative technical performance.
• 🤖 The company is seen as a significant beneficiary of AI-driven defense spending, with continued support from the administration.
• 🌐 Beyond government contracts, Palantir's commercial division is contributing significant revenue growth, particularly in AI.
• NATO's use of the Maven smart system highlights Palantir's differentiation.
• 📈 The stock's all-time high of $125.41 is considered a potential target, with strong fundamentals supporting its appreciation.